Jobs
-
UK-based Enterprise Therapeutics, which is developing inhaled ENaC blockers for the treatment of cystic fibrosis and other respiratory conditions, has named former Insmed Executive VP of Development and Chief Medical Officer Renu Gupta as the… Read more . . .
-
The Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS), announced that it has awarded approximately $40 million to CyanVac and approximately $34 million to CastleVax… Read more . . .
-
Firebrick Pharma, which recently launched its Nasodine povidone-iodine nasal spray in the US as a “nasal hygiene” product, has now announced the launch of Nasodine in Singapore as a germicidal product for protection against infection.… Read more . . .
-
CDMO Bespak says that it has already received new MDI filling equipment for one new LGWP propellant MDI manufacturing line at its Holmes Chapel, UK facility and that it has ordered equipment for another LGWP… Read more . . .
-
According to Agomab Therapeutics, the company’s AGMB-447 inhaled ALK5 inhibitor has received orphan drug designation from the FDA for the treatment of idiopathic pulmonary fibrosis (IPF). Agomab initiated a Phase 1 trial of AGMB-447 in… Read more . . .
-
CDMO Kindeva Drug Delivery has announced an expansion at its facility in Loughborough, UK to add dedicated laboratory space for analytical laboratory services. According to the company, the new Loughborough facility will double its lab space in… Read more . . .
-
According to Liquidia Corporation, a judge in the US District Court for the District of Delaware has denied a United Therapeutics motion seeking a preliminary injunction to prevent Liquidia from launching Yutrepia treprostinil DPI for the treatment… Read more . . .
-
Cardiff Scintigraphics, the parent company of inhalation CRO i2c Pharma Services, has named former OBG Pharmaceuticals Chief Scientific Officer Andrew Brown as CEO, succeeding Glyn Taylor, who will continue part time as Chief Scientific Officer.… Read more . . .
-
Milestone Pharmaceuticals announced that the FDA has accepted the company’s NDA for Cardaymyst etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone originally submitted the NDA in October 2023, and the FDA issued a… Read more . . .
-
According to SpliSense, the FDA has granted Fast Track designation to the company’s SPL84 inhaled antisense oligonucleotide for the treatment of cystic fibrosis. SPL84 had already received Orphan Drug designation from both the FDA and… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK